Scientists bioengineer a protein to fight leukemia

First report of a recombinant human biotherapeutic active against leukemic stem cells

2011-02-20

(Press-News.org) LOS ANGELES (February 18, 2011) – Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia. They have identified a protein called CD19-ligand (CD19-L) located on the surface of certain white blood cells that facilitates the recognition and destruction of leukemia cells by the immune system. This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent, targeting CD19-positive leukemic stem cells.

B-lineage acute lymphoblastic leukemia (ALL) is the most common cancer occurring in children and adolescents. Despite having received intensive chemotherapy, some patients have recurring disease. For these individuals, the prospect of long-term survival is poor.

"We need new anti-leukemia therapies capable of killing chemotherapy-resistant leukemia cells in patients with relapsed ALL. These are the cells that are the most difficult to treat. The challenge is to kill these cells while leaving healthy cells intact," said Fatih Uckun, MD, PhD, first author on the paper that has been published in the British Journal of Haematology. Dr. Uckun is also a professor of Pediatrics at the University of Southern California Keck School of Medicine and a member of the Developmental Therapeutics Program at the Norris Comprehensive Cancer Center.

Lymphocytes are a type of white blood cell involved in immune function and are categorized as either B-cells or T-cells. This newly discovered element, CD19-L, is expressed on the surface of T-lymphocytes and allows them to selectively bind to the CD19 receptor on the surface of B-lineage leukemia cells, and most importantly on leukemic stem cells responsible for the survival and expansion of the leukemia cell population. Once the CD19-L binds to leukemia cells, cell death occurs. Although CD19 is abundantly expressed on leukemia cells from B-lineage ALL patients, it is absent on red cells, T-cells, and normal bone marrow stem cells, making it specific, and therefore, a good therapeutic target.

Dr. Uckun and colleagues have bioengineered and prepared a highly purified liquid formulation of the human CD19-L protein. This recombinant protein not only shows selective binding to leukemia cells but also causes their rapid destruction within 24 hours. Perhaps most importantly, CD19-L killed even those leukemia cells that were highly resistant to both standard chemotherapy drugs as well as radiation.

CD19-L is the first CD19-specific recombinant human protein with potent anti-leukemic activity against B-lineage ALL, the most common form of childhood cancer and the second most common form of acute leukemia in adults. The identification of CD19-L may lead to therapeutic innovation for childhood leukemia by allowing a selective destruction of leukemic stem cells. According to Dr. Uckun, the next step will be to carefully evaluate this new agent for clinical potential against leukemia and to confirm in preclinical studies that leukemic cell destruction can be achieved at non-toxic dose levels.

"The CD19-ligand offers a previously unrecognized defense system against leukemia and opens a new range of therapeutic opportunities for the treatment of leukemia," said Stuart Siegel, MD, director of the Center for Cancer and Blood Diseases at Childrens' Hospital Los Angeles.

INFORMATION:

Recombinant human CD19-ligand protein as a potent anti-leukaemic agent. Uckun FM, Sun L, Qazi S, Ma H, Ozer Z. Br J Haematol. 2011. doi: 10.1111/j.1365-2141.2011.08583.x. [Epub ahead of print]

For more information, visit www.CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog: www.WeAreCHLA.org.

About Children's Hospital Los Angeles

Children's Hospital Los Angeles is one of the nation's top children's hospitals and is acknowledged worldwide for its leadership in pediatric and adolescent health. The Saban Research Institute of Children's Hospital Los Angeles is among the largest and most productive pediatric research facilities in the United States. Children's Hospital is a premier teaching hospital and has been affiliated with the Keck School of Medicine of the University of Southern California since 1932.

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

1 person of 1,900 met AHA's definition of ideal heart health, says University of Pittsburgh study

2011-02-20

PITTSBURGH, Feb. 18 – Only one out of more than 1,900 people evaluated met the American Heart Association (AHA) definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation. Ideal cardiovascular health is the combination of these seven factors: nonsmoking, a body mass index less than 25, goal-level physical activity and healthy diet, untreated cholesterol below 200, blood pressure below 120/80 and fasting blood sugar below 100, explained ...

Anti-aging hormone Klotho may prevent complications

2011-02-20

DALLAS – Feb. 17, 2011 – Low levels of the anti-aging hormone Klotho may serve as an early warning sign of the presence of kidney disease and its deadly cardiovascular complications, according to findings by UT Southwestern Medical Center researchers. Using mice, investigators found that soft-tissue calcification, a common and serious side effect of chronic kidney disease (CKD), improves when Klotho hormone levels are restored. The study is available online in the Journal of the American Society of Nephrology. The essential Klotho protein, which is produced by the kidneys, ...

How disordered proteins spread from cell to cell, potentially spreading disease

2011-02-20

One bad apple is all it takes to spoil the barrel. And one misfolded protein may be all that's necessary to corrupt other proteins, forming large aggregations linked to several incurable neurodegenerative diseases such as Huntington's, Parkinson's and Alzheimer's. Stanford biology Professor Ron Kopito has shown that the mutant, misfolded protein responsible for Huntington's disease can move from cell to cell, recruiting normal proteins and forming aggregations in each cell it visits. Knowing that this protein spends part of its time outside cells "opens up the possibility ...

A better way to diagnose pneumonia

2011-02-20

Researchers from the Georgia Institute of Technology have created a new sampling device that could prevent thousands of people worldwide from dying of pneumonia each year. Called PneumoniaCheck, the device created at Georgia Tech is a solution to the problem of diagnosing pneumonia, which is a major initiative of the U.S. Centers for Disease Control and Prevention (CDC). Pneumonia, an inflammation of the lungs, kills about 2.4 million people each year. The problem is particularly devastating in Africa, Southeast Asia and the Eastern Mediterranean, where a child dies ...

New model for probing antidepressant actions

2011-02-20

The most widely prescribed antidepressants – medicines such as Prozac, Lexapro and Paxil – work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes. That theory about how selective serotonin reuptake inhibitors (SSRIs) work can now be put to the test with a new mouse model developed by neuroscientists at Vanderbilt University. These mice, described in the online edition of the Proceedings of the National Academy of Sciences (PNAS), express a serotonin transporter that ...

Enhancing nuclear security: Training and international collaboration

2011-02-20

While a world free of nuclear weapons remains a goal for governments around the world, nuclear security constitutes a major challenge for the 21st century, as recognised at the 2010 nuclear security summit in Washington. Citizens are generally aware of international efforts to prevent the proliferation of nuclear weapons, but they are often unaware of nuclear security research and the important role science in this field. A new European nuclear security training centre and enhanced international collaboration are good examples. A recent survey on the EU´s radiological ...

Turning to nature for inspiration

2011-02-20

To build the next generation of sensors – with applications ranging from medical devices to robotics to new consumer goods – Chang Liu looks to biology. Liu, professor of mechanical engineering and electrical engineering and computer science at Northwestern University's McCormick School of Engineering and Applied Science, is using insights from nature as inspiration for both touch and flow sensors — areas that currently lack good sensors for recording and communicating the senses. Liu will discuss his research in a symposium at the annual meeting of the American Association ...

Plant breeding is being transformed by advances in genomics and computing

2011-02-20

The arrival of affordable, high throughput DNA sequencing, coupled with improved bioinformatics and statistical analyses is bringing about major advances in the field of molecular plant breeding. Multidisciplinary breeding programs on the world's major crop plants are able to investigate genome-wide variations in DNA sequences and link them to the inheritance of highly complex traits controlled by many genes, such as hybrid vigor. Furthermore, there has been a step-change in speed and cost-effectiveness. What previously took six generations to achieve can now be done in ...

AAAS Symposium: New research facilitates scientific knowledge transfer

2011-02-20

NEW YORK, February 4, 2011 –– A defining feature of a scientific discovery is replication by others. In today's age of computational science, this means higher standards of communication of discoveries — making available the data that generated the results along with the published research paper. Doing this makes the technology behind the finding widely accessible, facilitating re-use and verification of results. Tools and approaches to facilitate such knowledge transfer will be discussed at a symposium titled The Digitization of Science: Reproducibility and Interdisciplinary ...

Weight loss improves knee pain from common arthritic condition, study says

2011-02-20

SAN DIEGO, CA – Knee pain related to osteoarthritis (OA) is a common complaint among obese individuals and retired professional athletes, especially former NFL players, but researchers presenting their work at the American Orthopaedic Society for Sports Medicine's Specialty Day program (February 19th) say they have a simple solution: lose weight. "Our research on patients who were obese with early-onset knee osteoarthritis showed that those individuals who underwent isolated weight loss via bariatric surgery and lost an average of 57 pounds within the first six months ...

LAST 30 PRESS RELEASES:

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC